Table 1.
Baseline Characteristics and Prior Therapy of All Treated Patients*
| Variable | Concurrent Treatment (n=53) |
Sequenced Treatment (n=33) |
|---|---|---|
| Age - yr | ||
| Median | 58 | 64 |
| Range | 22-79 | 23-89 |
| Sex – no. (%) | ||
| Male | 32 (60) | 18 (55) |
| Female | 21 (40) | 15 (45) |
| ECOG performance status – no. (%) | ||
| 0 | 44 (83) | 22 (67) |
| 1 | 8 (15) | 11 (33) |
| Unknown | 1 (2) | 0 |
| M-stage at study entry – no. (%) | ||
| M1a | 8 (15) | 5 (15) |
| M1b | 11 (21) | 5 (15) |
| M1c | 30 (57) | 18 (55) |
| Unknown | 4 (8) | 5(15) |
| Lactate dehydrogenase level – no. (%) | ||
| ≤Upper limit of the normal range | 33 (62) | 21 (64) |
| >Upper limit of the normal range | 20 (38) | 12 (36) |
| Nature of prior therapy – no. (%) | ||
| Surgery | 51 (96) | 31 (94) |
| Radiotherapy | 11 (21) | 17 (52) |
| Systemic cancer therapy | 20 (38) | 33 (100) |
| Immunotherapy | 9 (17) | 33 (100) |
| Interleukin-2 | 8 (15) | 1 (3) |
| B-RAF inhibitor | 3 (6) | 2 (6) |
| Number of prior systemic cancer therapies – no. (%) | ||
| 0 | 33 (62) | 0 |
| 1 | 14 (26) | 18 (55) |
| 2 | 5 (9) | 10 (30) |
| ≥3 | 1 (2) | 5 (15) |
| Lesions at baseline – no. (%) | ||
| Bone | 5 (9) | 1 (3) |
| Central nervous system/brain | 0 | 1 (3) |
| Liver | 16 (30) | 13 (39) |
| Lung | 25 (47) | 16 (48) |
| Lymph node | 26 (49) | 8 (24) |
| Soft tissue/other organs | 34 (64) | 19 (58) |
*
ECOG denotes Eastern Cooperative Oncology Group.